Attenuated Salmonella typhi and Shigella as live oral vaccines and as live vectors.

Levine Mm(University of Maryland, Baltimore), Karen L. Kotloff(University of Maryland, Baltimore), Eileen M. Barry(University of Maryland, Baltimore), Fernando Noriega(Novavax (United States)), Carol O. Tacket(University of Maryland, Baltimore), G Losonsky, S Chatfield(University of Maryland, Baltimore), James E. Galen, Gordon Dougan(University of Cambridge), Marcelo B. Sztein(University of Maryland, Baltimore)
PubMed
February 1, 1997
Cited by 34

Related Papers

Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015
|The Lancet Infectious Diseases|2017|1.4k
Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18
|Nature|2001|1.3k
Global burden of Shigella infections: implications for vaccine development and implementation of control strategies.
|PubMed|1999|1.3k
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity
|Nature|2022|1.2k
Typhoid Fever
|New England Journal of Medicine|2002|1.1k